Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst Pharmaceuticals, Inc. (BCRX) will report its first quarter 2021 financial results on May 6, 2021. A conference call and webcast will occur at 8:30 a.m. ET to discuss the results and provide corporate updates. Interested parties can access the call via phone or through a live webcast on BioCryst's investor website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases, with products like ORLADEYO™ approved for HAE attacks and several ongoing development programs.
BioCryst Pharmaceuticals announced that Japan's National Health Insurance (NHI) system has approved ORLADEYO (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE), making it the first approved medication of its kind in the country. The NHI price listing will trigger a $15 million milestone payment to BioCryst from its partner Torii Pharmaceutical.
Additionally, BioCryst will receive tiered royalties on net sales in Japan. The medication has shown effectiveness in clinical trials, meeting primary endpoints for reducing HAE attacks.
BioCryst Pharmaceuticals (Nasdaq:BCRX) will present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:45 a.m. ET. The event will be streamed live via the Investors section of BioCryst’s website, with a replay available afterward. BioCryst focuses on developing oral medications for rare diseases, with products like ORLADEYO™ approved in the U.S. and Japan for HAE attack prevention. The company also has ongoing programs for additional treatments, including BCX9930 and BCX9250, targeting various rare conditions.
BioCryst Pharmaceuticals (BCRX) announced that its oral Factor D inhibitor, BCX9930, has shown significant efficacy in increasing hemoglobin levels and reducing transfusion requirements in treatment-naïve and C5 inhibitor inadequate response patients with paroxysmal nocturnal hemoglobinuria (PNH). In the trial, 100% of treatment-naïve patients and 83% of C5 inadequate response patients were transfusion-free. The mean hemoglobin levels increased significantly, and the drug was well-tolerated. Pivotal trials are expected to commence in the second half of 2021.
BioCryst Pharmaceuticals (BCRX) appointed Helen Thackray, M.D., FAAP, as chief research and development officer, a newly created position. Dr. Thackray will enhance BioCryst's R&D strategy, focusing on rare disease medicines. She brings extensive experience from GlycoMimetics, Inc. and a strong background in clinical development. CEO Jon Stonehouse expressed confidence in her ability to accelerate their programs. Dr. Thackray is excited about BioCryst's innovative pipeline of oral compounds targeting multiple rare diseases.
BioCryst Pharmaceuticals (Nasdaq:BCRX) will host a virtual R&D day on March 22, 2021, from 9:00 am to 11:00 am ET. The event will detail the company's innovative approach to developing oral medicines for rare diseases, highlighting BCX9930, an oral Factor D inhibitor for complement-mediated diseases.
New data from a trial with 16 paroxysmal nocturnal hemoglobinuria (PNH) patients will be presented. Attendees can access the live webcast at biocryst.com.
BioCryst Pharmaceuticals (BCRX) announced that the French National Agency for Medicines and Health Products Safety has granted a cohort ATU (Temporary Authorization for Use) for berotralstat, allowing its use in hereditary angioedema (HAE) patients aged 12 and older in France. This authorization enables earlier access to the drug prior to full EU marketing approval. The EU review is ongoing, with a decision anticipated in Q2 2021. Berotralstat, the first oral treatment for HAE, aims to prevent attacks effectively.
BioCryst Pharmaceuticals (BCRX) has submitted a marketing authorization application (MAA) to the UK's Medicines and Healthcare products Regulatory Agency for ORLADEYO™ (berotralstat), aimed at preventing recurrent hereditary angioedema (HAE) attacks in patients aged 12 and older. This submission follows a positive opinion from the European Medicines Agency's CHMP. If approved, ORLADEYO will be the first oral, once-daily therapy for HAE in the UK. The drug is already approved in the U.S. and Japan, with expectations for a decision from the European Commission in Q2 2021.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced a positive opinion from the CHMP of the EMA recommending approval for ORLADEYO™ (berotralstat) for preventing recurrent attacks of hereditary angioedema (HAE) in patients aged 12 and older. If approved by the European Commission, ORLADEYO would be the first oral, once-daily treatment for HAE in the EU. The CHMP's recommendation was based on positive results from pivotal clinical trials. ORLADEYO is already approved in the U.S. and Japan, with an Early Access Scheme approved in the UK.
BioCryst Pharmaceuticals (BCRX) reported its Q4 and full-year 2020 financial results, revealing total revenues of $4.0 million for Q4 and $17.8 million for the full year, down from $39.7 million and $48.8 million in 2019 respectively. The company launched ORLADEYO in the U.S. after FDA approval and received marketing approval in Japan. The financing raised $325 million in December 2020 aids the launch and ongoing development of BCX9930, with cash totaling $303 million expected to last into 2023. The net loss increased to $60.5 million in Q4, reflecting higher R&D and SG&A expenses.